SSTR1 Inhibitors
1 drugsAbout SSTR1
SSTR1 (somatostatin receptor 1) is a G protein-coupled receptor that binds the hormone somatostatin. This interaction triggers downstream effects impacting cell growth, hormone secretion, and neurotransmission.
Currently, there is no genetic evidence directly linking SSTR1 to specific diseases, limiting confidence in target validation.
SSTR1 is targeted by one approved drug, SIGNIFOR, a small molecule developed by RECORDATI RARE for one indication.
Top SSTR1 Drugs
RECORDATI RARE is the only company with an approved drug targeting SSTR1.
Low competition may present an opportunity, but also signals potential challenges in the therapeutic area.
SSTR1 Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets SSTR1, using small molecule modality.
Explore alternative modalities like antibodies or peptides to differentiate from existing therapies.
SSTR1 Clinical Trials 53 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on SSTR1. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 10 | 9 | 1 | 0 | 90% |
| Phase 2 | 29 | 15 | 11 | 3 | 58% |
| Phase 3 | 8 | 8 | 0 | 0 | 100% |
| Phase 4 | 6 | 4 | 1 | 1 | 80% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
SSTR1 Drug Approval Timeline (2012 - 2012)
The first and only drug, SIGNIFOR, was approved in 2012.
The lack of recent approvals suggests a saturated market or challenges in developing new SSTR1-targeting drugs.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 32 (3 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on SSTR1. A trial counts if an approved drug acting on SSTR1 is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.